CN110996974A - 增加免疫应答的材料和方法 - Google Patents

增加免疫应答的材料和方法 Download PDF

Info

Publication number
CN110996974A
CN110996974A CN201880052389.0A CN201880052389A CN110996974A CN 110996974 A CN110996974 A CN 110996974A CN 201880052389 A CN201880052389 A CN 201880052389A CN 110996974 A CN110996974 A CN 110996974A
Authority
CN
China
Prior art keywords
cells
mammal
naive
antigen receptor
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880052389.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·R·皮斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of CN110996974A publication Critical patent/CN110996974A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880052389.0A 2017-06-16 2018-06-15 增加免疫应答的材料和方法 Pending CN110996974A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762521011P 2017-06-16 2017-06-16
US62/521,011 2017-06-16
US201862618399P 2018-01-17 2018-01-17
US62/618,399 2018-01-17
PCT/US2018/037874 WO2018232318A1 (en) 2017-06-16 2018-06-15 Materials and methods for increasing immune responses

Publications (1)

Publication Number Publication Date
CN110996974A true CN110996974A (zh) 2020-04-10

Family

ID=64660538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052389.0A Pending CN110996974A (zh) 2017-06-16 2018-06-15 增加免疫应答的材料和方法

Country Status (8)

Country Link
US (1) US20200171170A1 (https=)
EP (1) EP3638262A4 (https=)
JP (2) JP7416629B2 (https=)
CN (1) CN110996974A (https=)
AU (2) AU2018283319B2 (https=)
CA (1) CA3067226A1 (https=)
MX (1) MX2019015183A (https=)
WO (1) WO2018232318A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2024238903A1 (en) * 2023-05-17 2024-11-21 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses within a mammal

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20030170212A1 (en) * 2001-05-15 2003-09-11 Zeling Cai Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
US20120121649A1 (en) * 2010-11-12 2012-05-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20120141537A1 (en) * 2010-11-18 2012-06-07 Pease Larry R Enhancing t cell activation using altered mhc-peptide ligands
US20120269860A1 (en) * 2009-10-27 2012-10-25 Alex Karlsson-Parra Method for Proliferation of Antigen-Specific T Cells
CN106574272A (zh) * 2014-08-29 2017-04-19 哥莫阿波单克隆有限责任公司 靶向多样的多种抗原的通用嵌合抗原受体表达性免疫细胞及其制造方法及其在癌症、感染和自身免疫病的治疗中的应用
WO2017075389A1 (en) * 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
US20190134091A1 (en) * 2015-06-12 2019-05-09 Lentigen Technology, Inc. Method to Treat Cancer with Engineered T-Cells
US20200016207A1 (en) * 2017-03-20 2020-01-16 Baylor College Of Medicine TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US7803382B2 (en) 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
CN1720326A (zh) 2002-10-01 2006-01-11 株式会社载体研究所 通过抑制tap活性增强mhcⅰ类分子对外来表位的展示的方法
CN107858333B (zh) 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20030170212A1 (en) * 2001-05-15 2003-09-11 Zeling Cai Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
US20120269860A1 (en) * 2009-10-27 2012-10-25 Alex Karlsson-Parra Method for Proliferation of Antigen-Specific T Cells
US20120121649A1 (en) * 2010-11-12 2012-05-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20120141537A1 (en) * 2010-11-18 2012-06-07 Pease Larry R Enhancing t cell activation using altered mhc-peptide ligands
CN106574272A (zh) * 2014-08-29 2017-04-19 哥莫阿波单克隆有限责任公司 靶向多样的多种抗原的通用嵌合抗原受体表达性免疫细胞及其制造方法及其在癌症、感染和自身免疫病的治疗中的应用
US20190134091A1 (en) * 2015-06-12 2019-05-09 Lentigen Technology, Inc. Method to Treat Cancer with Engineered T-Cells
WO2017075389A1 (en) * 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
CN108463548A (zh) * 2015-10-30 2018-08-28 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
US20200016207A1 (en) * 2017-03-20 2020-01-16 Baylor College Of Medicine TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADRIAN W. S. HO等: "Lung CD103+ Dendritic Cells Efficiently Transport Influenza Virus to the Lymph Node and Load Viral Antigen onto MHC Class I for Presentation to CD8 T Cells" *
EMILY CORSE等: "Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses" *
INAN EDES等: "In Vivo Transduction of T Cells: The Future of Immunotherapy?" *
LILI YANG等: "Engineered lentivector targeting of dendritic cells for in vivo immunization" *
NOAH J TUBO等: "Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection" *
杨滨燕等: "抗原特异性初始CD4~+T细胞的体内分化及特性" *
郑竹影: "大量扩增抗原特异性活化T细胞的方法研究" *

Also Published As

Publication number Publication date
EP3638262A4 (en) 2021-03-24
JP2024038256A (ja) 2024-03-19
JP7416629B2 (ja) 2024-01-17
EP3638262A1 (en) 2020-04-22
AU2018283319B2 (en) 2023-11-09
WO2018232318A1 (en) 2018-12-20
AU2018283319A1 (en) 2020-01-16
CA3067226A1 (en) 2018-12-20
AU2024200316A1 (en) 2024-02-08
JP2020524997A (ja) 2020-08-27
US20200171170A1 (en) 2020-06-04
MX2019015183A (es) 2020-02-20

Similar Documents

Publication Publication Date Title
Ma et al. The emerging field of oncolytic virus-based cancer immunotherapy
Osada et al. Dendritic cell-based immunotherapy
CN106659742B (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
US12569562B2 (en) Pretreatment drug for T cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
US6207147B1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
Huang et al. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
BG106028A (bg) Имунотерапия на рак чрез експресия на скъсен туморен или тумор-асоцииран антиген
Smits et al. Immunotherapy of acute myeloid leukemia: current approaches
Williams et al. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector
EP1729798A1 (en) Antigen specific t cell therapy
US20200016254A1 (en) Neoepitope vaccine and minnune stimulant combinations and methods
Mierzejewska et al. The beneficial effect of IL‐12 and IL‐18 transduced dendritic cells stimulated with tumor antigens on generation of an antitumor response in a mouse colon carcinoma model
JP2024038256A (ja) 免疫応答を増強するための物質および方法
Dissanayake et al. Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant
JP2019500028A (ja) 癌免疫療法で使用するための二重特異性ｔ細胞を製造する方法
US11564980B2 (en) Tumor treatment method with an individualized peptide vaccine
Xia et al. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
Hu et al. Genetically modified cancer vaccines: Current status and future prospects
Castillo et al. Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
CN103933558B (zh) 一种新型、广谱的治疗性肿瘤疫苗的制备和使用方法
JP2021536247A (ja) 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
WO2025152901A1 (zh) 一种用于肿瘤治疗的溶瘤病毒-t细胞嵌合体及其应用
Komant et al. Oncolytic vaccinia virus as a precision cancer vaccine platform
Qi et al. Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination